PMID: 7334406Dec 1, 1981Paper

Growth hormone and prolactin stimulation by Madopar in Parkinson's disease

Journal of Neurology, Neurosurgery, and Psychiatry
A Martinez-CamposE E Müller

Abstract

Madopar, a combination of levodopa with benserazide, induced an inconsistent rise in plasma growth hormone in unmedicated patients with Parkinson's disease and in controls, and a greater growth hormone rise in Parkinsonian subjects on chronic Madopar therapy. In subjects on chronic therapy with levodopa and carbidopa (Sinemet), the growth hormone releasing effect of Madopar was blunted. Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. Since these data were interpreted as due to a defective dopamine tone in the hypothalamus of Parkinsonian subjects on Madopar but not Sinemet therapy, a direct dopamine receptor agonist, lisuride was administered. Lisuride, however, elicited a blunted growth hormone response both in patients on Madopar and Sinemet therapy, without revealing a state of supersensitivity of dopamine receptors for growth hormone control in Parkinsonian subjects on Madopar therapy. No difference was present in the PRL-lowering effect of lisuride in the different experimental groups. These findings suggest that: (1) hypothalamic dopamine function is impaired in Parkin...Continue Reading

References

Feb 21, 1976·Lancet·H A ZacurJ E Tyson
Nov 1, 1979·Psychopharmacology·E K Silbergeld, R E Hruska
Dec 1, 1978·The Journal of Clinical Endocrinology and Metabolism·E E MüllerS Murru
Oct 1, 1977·The Journal of Clinical Endocrinology and Metabolism·P D WoolfL A Lee
Dec 1, 1979·Neurology·U K Rinne, P Mölsä
Jan 1, 1975·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·G Bartholini, A Pletscher
Jul 1, 1976·The Journal of Clinical Endocrinology and Metabolism·G M BrownH C Stancer
Jan 1, 1975·The Journal of Clinical Endocrinology and Metabolism·I MaanyJ Mendels
Jun 1, 1975·The Journal of Clinical Endocrinology and Metabolism·P EttigiH G Friesen
Dec 22, 1972·Science·E J SacharJ Sassin
May 1, 1973·Clinical Pharmacology and Therapeutics·H Mars, S M Genuth
Nov 1, 1980·Journal of Neurology, Neurosurgery, and Psychiatry·N F Lawton, J MacDermot
Jul 10, 1980·Nature·M SchachterR Dorow
Apr 1, 1981·Endocrinology·F CasanuevaE E Müller

❮ Previous
Next ❯

Citations

Dec 10, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·J KimberC J Mathias
Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·R VolpiV Coiro
Jan 1, 1991·Journal of Psychiatric Research·M MaesP Cosyns
Jan 1, 1987·Journal of Psychosomatic Research·R D LaneA M Ostfeld
Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·D F DarkoD S Janowsky
Jun 1, 1986·Biological Psychology·J HerbertF N Watts
Mar 1, 1991·Baillière's Clinical Endocrinology and Metabolism·L G Sobrinho
May 1, 1987·Baillière's Clinical Endocrinology and Metabolism·J Herbert
Mar 1, 1991·Acta Neurologica Scandinavica·G CusimanoG Meco
Nov 1, 1988·Medical Toxicology and Adverse Drug Experience·K Hell, H Wernze
Nov 18, 2014·Acta Neurologica Scandinavica·M NitkowskaA Friedman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.